SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey.
J Med Virol
; 94(4): 1711-1716, 2022 Apr.
Article
Dans Anglais
| MEDLINE | ID: covidwho-1718398
ABSTRACT
The persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is a matter of importance regarding the coronavirus disease 19 (COVID-19) pandemic. To observe antibody dynamics, 105 blood donors, positive for SARS-CoV-2 antibodies by a lateral flow test within a seroprevalence study, were included in this study. Thirty-nine (37%) of 105 the donors were confirmed positive by a total Ig Wantai enzyme-linked immunosorbent assay (ELISA). Three (8%) in this group of 39 reported severe and 26/39 (67%) mild to moderate COVID-19 symptoms. By further ELISA-testing, 33/39 (85%) donors were initially positive for IgG antibodies, 31/39 (79%) for IgA, and 32/39 (82%) for IgM, while 27/39 (69%) were positive for all three isotypes. Persistence of IgG, IgA, and IgM was observed in 73%, 79%, and 32% of donors, respectively, after 6-9 months of observation. For IgM antibodies, the decline in the proportion of positive donors was statistically significant (p = 0.002) during 12 months observation, for IgG only the decline at 3 months was statistically significant (p = 0.042). Four donors exhibited notable increases in antibody levels. In conclusion, persistent SARS-CoV-2 IgA antibodies and IgG antibodies at 6-9 months are present in approximately three of four individuals with previous mild to moderate COVID-19.
Mots clés
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Donneurs de sang
/
SARS-CoV-2
/
COVID-19
/
Anticorps antiviraux
Type d'étude:
Étude observationnelle
/
Étude pronostique
Les sujets:
Covid long
Limites du sujet:
Adulte
/
Femelle
/
Humains
/
Mâle
/
Jeune adulte
Pays comme sujet:
Europe
langue:
Anglais
Revue:
J Med Virol
Année:
2022
Type de document:
Article
Pays d'affiliation:
Jmv.27486
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS